Teleflex stock
TFXNYSETeleflex Incorporated, HealthcareISIN US8793691069
59Score 59 out of 100, Neutral
Price and trend
77 / 100
Price history
+39% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since April 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 86).
The price is at its 52-week high. Largest decline in 20 years: 77% (April 2021 to January 2026).
Chart figures for advanced users
- SMA 50$133.02
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$127.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)86
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$100.34
- The lowest closing price of the last twelve months.
- Resistance$156.33
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Teleflex Incorporated belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $6.2B, is number 21 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.99B (down 34.6% year on year) and a loss of $905.64M.
- MEQIRI Score 59 out of 100 (Neutral): rank 293 of 714 in Healthcare, median 53.
Show more
- The P/E is 74.2 (Medical (Instruments & Supplies) median 34.8, own median of recent years 37.7).
- Our model puts fair value at $97.35, with the price 61% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 39 years.
- Analysts expect strong earnings growthUp 23.2% a year through 2028 (estimates from 7 analysts).Growth 50
Weaknesses
- Interest barely coveredOperating profit covers interest only 1.2 times.Stability 59
- Above fair valuePrice 61% above the fair value of $97.35.Valuation 19
- Richly valuedP/E 74.2, Medical (Instruments & Supplies) median 34.8, own median 37.7.Valuation 19
Its standout strengths are momentum and technical analysis, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedIn our model the price counts as cheap below $74.89 and expensive above $139.07 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $121.49 (cash-flow model) and $73.22 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $86.97, at 7.8% it would be $112.95.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue fell 37.8% on the same quarter a year earlier. Up to 2024 the bars include businesses that were later spun off or sold. On a comparable basis, as restated in the SEC annual reports, revenue grew 6.4% a year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 56%, operating 13%, net not measured.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $2.63 (expected $1.90)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $7.22+0.2%
- Revenue
- $2.27B0.0%
- Earnings per share
- $10.950.0%
- Revenue
- $2.37B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook mixed
Share price after the results: −1.3%2026 revenue growth cut to 3.5% to 4.5% (previously 4.5% to 5.5%), but adjusted EPS raised to $6.90 to $7.20 (previously $6.25 to $6.55).
“We now expect pro forma adjusted constant currency revenue growth for 2026 to be in a range of 3.5% to 4.5% as compared to 4.5% to 5.5% previously.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Teleflex
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- AptarGroupATR $9.07B65
- Bausch + LombBLCO $7.62B50
- Asahi Intecc7747.T $6.34B83
- Gan & Lee Pharmaceuticals.603087.SS $6.21B56
- Merit Medical SystemsMMSI $5.28B61
- ICU MedicalICUI $4.46B54
- Pulse BiosciencesPLSE $4.19B46
- Envista HoldingsNVST $4.06B72
ETFs that hold Teleflex
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.36% | 0.30% | €2.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.16% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.13% | 0.35% | €434.1M |
Show 5 more
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.11% | 0.30% | €944.34M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.06% | 0.35% | €8.19B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.02% | 0.25% | €175.89M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.01% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 27 Oct 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.